BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Mezagitamab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Mezagitamab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06722235-3188@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20280316
DTEND;VALUE=DATE:20280317
SUMMARY:Mezagitamab: Phase 3 readout est. (NCT06722235)
DESCRIPTION:Mezagitamab\, phase 3.\nStudy: A Study of Mezagitamab in Adults
  With Chronic Primary Immune Thrombocytopenia\nEstimated primary completio
 n: 16 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mez
 agitamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06722235
URL:https://assetmemo.bio/drug/mezagitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06963827-3188@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20280907
DTEND;VALUE=DATE:20280908
SUMMARY:Mezagitamab: Phase 3 readout est. (NCT06963827)
DESCRIPTION:Mezagitamab\, phase 3\, Chronic Kidney Disease.\nStudy: A Study
  of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy\nEs
 timated primary completion: 7 September 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/mezagitamab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06963827
URL:https://assetmemo.bio/drug/mezagitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07613359-3188@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20290115
DTEND;VALUE=DATE:20290116
SUMMARY:Mezagitamab: Phase 2 readout est. (NCT07613359)
DESCRIPTION:Mezagitamab\, phase 2.\nStudy: A Study of Mezagitamab in Adults
  With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant\nEs
 timated primary completion: 15 January 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/mezagitamab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07613359
URL:https://assetmemo.bio/drug/mezagitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06948318-3188@assetmemo.bio
DTSTAMP:20261121T005430Z
DTSTART;VALUE=DATE:20290729
DTEND;VALUE=DATE:20290730
SUMMARY:Mezagitamab: Phase 3 readout est. (NCT06948318)
DESCRIPTION:Mezagitamab\, phase 3.\nStudy: A Follow-up Study of Mezagitamab
  in Adults With Chronic Primary Immune Thrombocytopenia\nEstimated primary
  completion: 29 July 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/mezagitamab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06948318
URL:https://assetmemo.bio/drug/mezagitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
